JP2022509091A5 - - Google Patents

Info

Publication number
JP2022509091A5
JP2022509091A5 JP2021527206A JP2021527206A JP2022509091A5 JP 2022509091 A5 JP2022509091 A5 JP 2022509091A5 JP 2021527206 A JP2021527206 A JP 2021527206A JP 2021527206 A JP2021527206 A JP 2021527206A JP 2022509091 A5 JP2022509091 A5 JP 2022509091A5
Authority
JP
Japan
Prior art keywords
compound according
compound
pharmaceutically acceptable
acceptable salt
stereoisomers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021527206A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022509091A (ja
JP7509772B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/062054 external-priority patent/WO2020106642A1/en
Publication of JP2022509091A publication Critical patent/JP2022509091A/ja
Publication of JP2022509091A5 publication Critical patent/JP2022509091A5/ja
Application granted granted Critical
Publication of JP7509772B2 publication Critical patent/JP7509772B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021527206A 2018-11-19 2019-11-18 ヘモグロビンのモジュレーター Active JP7509772B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201862769196P 2018-11-19 2018-11-19
US62/769,196 2018-11-19
US201962821314P 2019-03-20 2019-03-20
US62/821,314 2019-03-20
US201962848773P 2019-05-16 2019-05-16
US62/848,773 2019-05-16
US201962883313P 2019-08-06 2019-08-06
US62/883,313 2019-08-06
PCT/US2019/062054 WO2020106642A1 (en) 2018-11-19 2019-11-18 2-formyl-3-hydroxyphenyloxymethyl compounds capable of modulating hemoglobin

Publications (3)

Publication Number Publication Date
JP2022509091A JP2022509091A (ja) 2022-01-20
JP2022509091A5 true JP2022509091A5 (https=) 2023-07-26
JP7509772B2 JP7509772B2 (ja) 2024-07-02

Family

ID=68848454

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021527206A Active JP7509772B2 (ja) 2018-11-19 2019-11-18 ヘモグロビンのモジュレーター

Country Status (29)

Country Link
US (4) US10683285B2 (https=)
EP (2) EP4046988A1 (https=)
JP (1) JP7509772B2 (https=)
KR (1) KR102842589B1 (https=)
CN (1) CN113316568B (https=)
AU (1) AU2019383960B2 (https=)
BR (1) BR112021007044B1 (https=)
CA (1) CA3120380A1 (https=)
CO (1) CO2021007993A2 (https=)
CR (1) CR20210335A (https=)
CY (1) CY1125025T1 (https=)
DK (1) DK3880654T3 (https=)
ES (1) ES2908325T3 (https=)
HR (1) HRP20220295T1 (https=)
HU (1) HUE057323T2 (https=)
IL (1) IL283128B2 (https=)
LT (1) LT3880654T (https=)
MA (1) MA54231B1 (https=)
MD (1) MD3880654T2 (https=)
MX (1) MX2021005887A (https=)
PL (1) PL3880654T3 (https=)
PT (1) PT3880654T (https=)
RS (1) RS62970B1 (https=)
SA (1) SA521422031B1 (https=)
SG (1) SG11202104705RA (https=)
SI (1) SI3880654T1 (https=)
SM (1) SMT202200106T1 (https=)
TW (1) TWI841630B (https=)
WO (1) WO2020106642A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
EP3919056B1 (en) 2013-03-15 2024-08-28 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
SG10201802911RA (en) 2013-03-15 2018-05-30 Global Blood Therapeutics Inc Compounds and uses thereof for the modulation of hemoglobin
AP2015008718A0 (en) 2013-03-15 2015-09-30 Global Blood Therapeutics Inc Compounds and uses thereof for the modulation of hemoglobin
ES2860648T5 (es) 2014-02-07 2024-11-27 Global Blood Therapeutics Inc Polimorfos cristalinos de la base libre de 2-hidroxi-6-((2-(1-isopropil-1H-pirazol-5-il)piridin-3-il)metoxi)benzaldehído
US11020382B2 (en) 2015-12-04 2021-06-01 Global Blood Therapeutics, Inc. Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
LT3483164T (lt) 2017-03-20 2020-05-11 Forma Therapeutics, Inc. Pirolpirolo kompozicijos kaip piruvato kinazės (pkr) aktyvatoriai
EP3853206B1 (en) 2018-09-19 2024-04-10 Novo Nordisk Health Care AG Treating sickle cell disease with a pyruvate kinase r activating compound
EP3852791B1 (en) 2018-09-19 2024-07-03 Novo Nordisk Health Care AG Activating pyruvate kinase r
EP3860975B1 (en) 2018-10-01 2023-10-18 Global Blood Therapeutics, Inc. Modulators of hemoglobin for the treatment of sickle cell disease
HRP20220295T1 (hr) * 2018-11-19 2022-05-13 Global Blood Therapeutics, Inc. Spojevi 2-formil-3-hidroksifeniloksimetila koji mogu modulirati hemoglobin
HRP20251148T1 (hr) 2019-09-19 2025-11-21 Novo Nordisk Health Care Ag Pripravci koji aktiviraju piruvat-kinazu r (pkr)
CA3176429A1 (en) * 2020-03-31 2021-10-07 Global Blood Therapeutics, Inc. Modulators of hemoglobin
US12128035B2 (en) 2021-03-19 2024-10-29 Novo Nordisk Health Care Ag Activating pyruvate kinase R
WO2022241286A1 (en) 2021-05-14 2022-11-17 Global Blood Therapeutics, Inc. Methods of making a modulator of hemoglobin
CA3219786A1 (en) 2021-05-14 2022-11-17 Global Blood Therapeutics, Inc. Solid forms of a modulator of hemoglobin
US20240316184A1 (en) 2021-07-19 2024-09-26 Bioapplications Inc. Plant-based covid-19 variant recombinant spike protein expression vector and recombinant protein using same
US20250041312A1 (en) 2021-12-10 2025-02-06 Global Blood Therapeutics, Inc. Methods of administering a modulator of hemoglobin
TW202515579A (zh) 2023-06-13 2025-04-16 美商全球血液治療公司 投予血紅素的調節劑之方法
WO2025262596A1 (en) 2024-06-20 2025-12-26 Pfizer Inc. Methods of making osivelotor

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
DE3061269D1 (en) 1979-06-29 1983-01-13 Wellcome Found Substituted phenol ethers, their preparation, intermediates therefor, pharmaceutical compositions containing them and the preparation thereof
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
ZA818741B (en) 1980-12-18 1983-07-27 Wellcome Found Pharmaceutical compounds,preparation,use and intermediates therefor and their preparation
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
JPS63258463A (ja) 1987-04-14 1988-10-25 Kumiai Chem Ind Co Ltd 2−フエノキシピリミジン誘導体及び除草剤
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
EP0658559A1 (de) 1993-12-14 1995-06-21 Chemisch Pharmazeutische Forschungsgesellschaft m.b.H. Thienothiazinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als 5-dipoxygenase und Cyclooxygenaseinhibitoren
KR100473966B1 (ko) 1998-12-14 2005-03-08 에프. 호프만-라 로슈 아게 페닐글리신 유도체
CA2368703A1 (en) 1999-03-31 2000-10-12 Basf Aktiengesellschaft Substituted aniline compounds
BR0313160A (pt) 2002-08-08 2005-07-12 Smithkline Beecham Corp Composto, composição farmacêutica, métodos para tratar uma condição e um neoplasmo suscetìvel em um animal em um animal, processo para preparar um composto e uso de um composto
EP2179987B1 (en) 2002-12-04 2013-02-13 Virginia Commonwealth University Use of heterocyclic carbaldehyde derivatives against sickle cell anemia
RU2337908C2 (ru) 2003-06-12 2008-11-10 Ново Нордиск А/С Пиридинилкарбаматы в качестве ингибиторов гормон-чувствительной липазы
WO2005102305A2 (en) 2004-04-22 2005-11-03 Allos Therapeutics, Inc. Compositions of allosteric hemoglobin modifiers and methods of making the same
MX2007016508A (es) 2005-06-30 2008-03-04 Prosidion Ltd Agonistas del receptor acoplado a la proteina g.
CN100562514C (zh) 2005-07-22 2009-11-25 中国科学院上海药物研究所 一类取代丙酰胺衍生物、其制备方法和用途
WO2008066145A1 (en) 2006-11-30 2008-06-05 R-Tech Ueno, Ltd. Thiazole derivative and use thereof as vap-1 inhibitor
WO2009011850A2 (en) 2007-07-16 2009-01-22 Abbott Laboratories Novel therapeutic compounds
JP5436544B2 (ja) 2008-05-08 2014-03-05 ノヴァ サウスイースタン ユニバーシティ− 血管内皮増殖因子受容体に特異的な阻害剤
GB0811451D0 (en) 2008-06-20 2008-07-30 Syngenta Participations Ag Novel microbiocides
TW201033201A (en) 2009-02-19 2010-09-16 Hoffmann La Roche Isoxazole-isoxazole and isoxazole-isothiazole derivatives
WO2013102142A1 (en) 2011-12-28 2013-07-04 Global Blood Therapeutics, Inc. Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation
HK1203412A1 (en) 2011-12-28 2015-10-30 Global Blood Therapeutics, Inc. Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation
US9802900B2 (en) 2013-03-15 2017-10-31 Global Blood Therapeutics, Inc. Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin
US9422279B2 (en) * 2013-03-15 2016-08-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
SG10201802911RA (en) 2013-03-15 2018-05-30 Global Blood Therapeutics Inc Compounds and uses thereof for the modulation of hemoglobin
US9458139B2 (en) 2013-03-15 2016-10-04 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
WO2014145040A1 (en) 2013-03-15 2014-09-18 Global Blood Therapeutics, Inc. Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation
CN105209469A (zh) * 2013-03-15 2015-12-30 全球血液疗法股份有限公司 化合物及其用于调节血红蛋白的用途
US9604999B2 (en) 2013-03-15 2017-03-28 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
EP3919056B1 (en) 2013-03-15 2024-08-28 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US20140271591A1 (en) 2013-03-15 2014-09-18 Global Blood Therapeutics, Inc. Compositions and methods for the modulation of hemoglobin (s)
US20150057251A1 (en) 2013-08-26 2015-02-26 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10266551B2 (en) * 2013-03-15 2019-04-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US20140274961A1 (en) 2013-03-15 2014-09-18 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
WO2015031284A1 (en) 2013-08-26 2015-03-05 Global Blood Therapeutics, Inc. Formulations comprising wetting agents and compounds for the modulation of hemoglobin (s)
US20160207904A1 (en) 2013-08-27 2016-07-21 Global Blood Therapeutics, Inc. Crystalline 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde ansolvate salts
US20150141465A1 (en) 2013-11-18 2015-05-21 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
EA202092627A1 (ru) 2013-11-18 2021-09-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
US9248199B2 (en) 2014-01-29 2016-02-02 Global Blood Therapeutics, Inc. 1:1 adducts of sickle hemoglobin
ES2860648T5 (es) 2014-02-07 2024-11-27 Global Blood Therapeutics Inc Polimorfos cristalinos de la base libre de 2-hidroxi-6-((2-(1-isopropil-1H-pirazol-5-il)piridin-3-il)metoxi)benzaldehído
MA41841A (fr) 2015-03-30 2018-02-06 Global Blood Therapeutics Inc Composés aldéhyde pour le traitement de la fibrose pulmonaire, de l'hypoxie, et de maladies auto-immunes et des tissus conjonctifs
US11020382B2 (en) 2015-12-04 2021-06-01 Global Blood Therapeutics, Inc. Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
TWI825524B (zh) 2016-05-12 2023-12-11 美商全球血液治療公司 用於合成2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)-吡啶-3-基)甲氧基)苯甲醛之方法
TW202332423A (zh) 2016-10-12 2023-08-16 美商全球血液治療公司 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑
HRP20220295T1 (hr) * 2018-11-19 2022-05-13 Global Blood Therapeutics, Inc. Spojevi 2-formil-3-hidroksifeniloksimetila koji mogu modulirati hemoglobin

Similar Documents

Publication Publication Date Title
JP2022509091A5 (https=)
KR102695128B1 (ko) 고리 변형된 프롤린 쇼트 펩티드 화합물 및 이의 용도
JP2024512154A5 (https=)
HRP20220295T1 (hr) Spojevi 2-formil-3-hidroksifeniloksimetila koji mogu modulirati hemoglobin
MX2024001929A (es) Composiciones de polvo seco de profarmacos de treprostinil y metodos de uso de las mismas.
RU2009102278A (ru) Модуляторы рецептора s1p для лечения рассеянного склероза
JP2021514001A5 (https=)
JP2013010792A5 (https=)
JP2008539268A5 (https=)
JP2023531709A5 (https=)
CN107848952B (zh) 稠合三环γ-氨基酸衍生物及其制备方法和在医药上的应用
CA2541781A1 (en) 3-hydroxymethyl-4-hydroxy-phenyl derivatives for the treatment of respiratory illnesses
JP2009541224A5 (https=)
JP2017522304A5 (https=)
JP2022505268A5 (https=)
JP2022506059A5 (https=)
MX2023004812A (es) Composiciones de polvo seco de profarmacos de treprostinil y metodos de uso de estos.
JP2015502371A5 (https=)
JP2022523668A5 (https=)
JP2024509981A5 (https=)
JP2024511832A5 (https=)
JP2008526950A5 (https=)
RU2019109570A (ru) 8-(азетидин-1-ил)-[1,2,4]триазоло[1,5-а]пиридинилы, композиции и способы их применения
JP2007525533A5 (https=)
RU2015106013A (ru) Соединения пиразолкарбоксамида, композиции и способы применения